reports
Gilat Reports First Quarter 2024 Results
Gilat Reports First Quarter 2024 Results Strong Revenue Growth of 29% Year-over-Year, GAAP Operating Income of $5.4 Million and Adjusted EBITDA of $9.3 Million PETAH TIKVA, Israel, May 08, 2024 (GLOBE NEWSWIRE) -- Gilat Satellite Networks Ltd. (NASDAQ: GILT, TASE: GILT), a worldwide leader in satellite networking technology, solutions and services, today reported its results for the first quarter, ended March 31, 2024. First Quarter 2024 Financial Highlights Revenue of $76.1 million, up 29% compared with $59.0 million in Q1 2023;GAAP operating income of $5.4 million, c...
Celcuity Inc. Schedules Release of First Quarter 2024 Financial Result...
Celcuity Inc. Schedules Release of First Quarter 2024 Financial Results and Webcast/Conference Call MINNEAPOLIS, May 08, 2024 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced that it will release its financial results for the first quarter 2024 after the market closes on Wednesday, May 15, 2024. Management will host a webcast/teleconference the same day at 4:30 p.m. Eastern Time to discuss the results and provide a corporate update. Webcast and Conference Call Information To ...
Vertex Announces First Quarter 2024 Financial Results
Vertex Announces First Quarter 2024 Financial Results KING OF PRUSSIA, Pa., May 08, 2024 (GLOBE NEWSWIRE) -- Vertex, Inc. (NASDAQ: VERX) (“Vertex” or the “Company”), a leading global provider of indirect tax solutions, today announced financial results for its first quarter ended March 31, 2024. “The year is off to a solid start, and I am very pleased with our financial performance in the first quarter,” stated David DeStefano, Vertex’s President, Chief Executive Officer and Chairperson of the Board. “Revenue traction is strong in the first quarter, with our cloud solutions leading the w...
Olema Oncology Announces New Clinical Data for Palazestrant in Combina...
Olema Oncology Announces New Clinical Data for Palazestrant in Combination with Ribociclib to be Presented at the 2024 ESMO Breast Cancer Annual Congress Olema will host an investor conference call at 8:00 a.m. ET on May 15, 2024 SAN FRANCISCO, May 08, 2024 (GLOBE NEWSWIRE) -- (“Olema” or “Olema Oncology,” Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted therapies for women’s cancers, today announced that it will present new clinical data from the Company’s ongoing Phase 1b/2 clinical study of palazestrant...
Black Diamond Group Limited Announces Renewal of Normal Course Issuer ...
Black Diamond Group Limited Announces Renewal of Normal Course Issuer Bid CALGARY, Alberta, May 08, 2024 (GLOBE NEWSWIRE) -- Black Diamond Group Limited (TSX: BDI) (“Black Diamond” or the “Company”) announces that it has obtained approval of the Toronto Stock Exchange (the “TSX”) to renew its normal course issuer bid (the “NCIB”) with respect to its common shares (the “Common Shares”). The NCIB will commence on May 10, 2024, and will terminate on the earlier of May 9, 2025, the date on which the Company has purchased the maximum number of Common Shares permitted under the NCIB or the date...
SpringWorks Therapeutics to Participate in the BofA Securities 2024 He...
SpringWorks Therapeutics to Participate in the BofA Securities 2024 Health Care Conference STAMFORD, Conn., May 08, 2024 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a commercial-stage biopharmaceutical company focused on severe rare diseases and cancer, today announced that management will participate in a fireside chat at the BofA Securities 2024 Health Care Conference, taking place in Las Vegas, Nevada on Tuesday, May 14, 2024 at 3:40 p.m. PT / 6:40 p.m. ET. To access the live webcast, please visit the Events & Presentations page within the Investors & Media sect...
Sprott Announces First Quarter 2024 Results
Sprott Announces First Quarter 2024 Results TORONTO, May 08, 2024 (GLOBE NEWSWIRE) -- Sprott Inc. (NYSE/TSX: SII) (“Sprott” or the “Company”) today announced its financial results for the quarter ended March 31, 2024. Management commentary “Sprott’s AUM once again reached record highs during the quarter, driven by stronger gold and silver prices late in the period, offset somewhat by what we view as short-term weakness in uranium and related equities. As of March 31, 2024, AUM was $29.4 billion, up $0.6 billion from the end of 2023. Subsequent to quarter end, on May 6, 2024, AUM stood at...
Brink's Announces Strong First-Quarter Results and Affirms Full Year G...
Brink's Announces Strong First-Quarter Results and Affirms Full Year Guidance Record First Quarter Revenue Reflecting 4% Growth and 12% Organic GrowthGAAP net income up 229% to $49M and record adjusted EBITDA up 15% to $218MGAAP EPS up 263% to $1.09 and non-GAAP EPS up 20% to $1.52TTM GAAP Net Cash from Operations up 56% to $800M: non-GAAP Free Cash Flow up 61% to $363M RICHMOND, Va., May 08, 2024 (GLOBE NEWSWIRE) -- The Brink’s Company (NYSE:BCO), a leading global provider of cash and valuables management, digital retail solutions (DRS), and ATM managed services (AMS), today announced f...
Tata Consumer Products Ltd: 1 director
A director at Tata Consumer Products Ltd sold 27,000 shares at 1,095.950INR and the significance rating of the trade was 60/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two...
Xiabuxiabu Catering Management (China) Holdings Co. Ltd: 1 director
A director at Xiabuxiabu Catering Management (China) Holdings Co. Ltd bought 18,075,000 shares at 1.607HKD and the significance rating of the trade was 68/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the compan...
- ABGSC Telecom Operators Research
- Oscar Rönnkvist
- Øystein Elton Lodgaard
- Simon Granath
GDS to Report First Quarter 2024 Financial Results Before the Open of ...
GDS to Report First Quarter 2024 Financial Results Before the Open of the U.S. Market on May 22, 2024 SHANGHAI, China, May 08, 2024 (GLOBE NEWSWIRE) -- GDS Holdings Limited (“GDS Holdings”, “GDS” or the “Company”) (NASDAQ: GDS; HKEX: 9698), a leading developer and operator of high-performance data centers in China and South East Asia, today announced that it will report its first quarter 2024 unaudited financial results after the close of the Hong Kong market and before the open of the U.S. market on May 22, 2024. The Company’s management will host an earnings conference call at 8:00 AM ...
Sage launches two new integrated suites in Canada and the UK to help A...
Sage launches two new integrated suites in Canada and the UK to help Accountants and Small Businesses drive growth Sage for Accountants will streamline everything from proposals to advisory services for a seamless practice experience Sage for Small Business combines accounting, payroll, and HR tools into one comprehensive suite for essential business operations TORONTO, May 08, 2024 (GLOBE NEWSWIRE) -- , the leader in accounting, financial, HR, and payroll technology for small and mid-sized businesses (SMBs), has launched two new suites in Canada and the UK, to transform how SMBs a...
Sage lance deux nouvelles suites intégrées au Canada et au Royaume-Uni...
Sage lance deux nouvelles suites intégrées au Canada et au Royaume-Uni pour aider les comptables et les petites entreprises à stimuler leur croissance Sage pour Comptables simplifiera tout, et ce, des propositions aux services-conseils pour favoriser une expérience cabinet en continu Sage pour Petites entreprises regroupe les outils de comptabilité, de paie et des ressources humaines en une suite complète pour effectuer des opérations d’affaires importantes TORONTO, 08 mai 2024 (GLOBE NEWSWIRE) -- , le chef de file des technologies comptables, financières, RH et paie pour les petites ...
Kymera Therapeutics to Participate in Upcoming May Investor Conference...
Kymera Therapeutics to Participate in Upcoming May Investor Conferences WATERTOWN, Mass., May 08, 2024 (GLOBE NEWSWIRE) -- (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of small molecule medicines using targeted protein degradation (TPD), today announced that the Company will participate in fireside chats at the following upcoming investor events: BofA Securities 2024 Health Care Conference in Las Vegas, NV on May 15 at 4:20 p.m. PT; andTD Cowen 5th Annual Oncology Innovation Virtual Summit on May 28 at 1:30 p.m. ET. Live webcasts of the presentations...
Aura Biosciences to Participate in Upcoming Investor Conferences
Aura Biosciences to Participate in Upcoming Investor Conferences BOSTON, May 08, 2024 (GLOBE NEWSWIRE) -- Aura Biosciences, Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing precision immunotherapies to treat solid tumors designed to preserve the function of the organ with cancer, today announced that Elisabet de los Pinos, PhD, Chief Executive Officer, will participate in the following upcoming investor conferences: The Citizens JMP Life Sciences Conference on Monday, May 13, 2024.Fireside Chat at 9:00 a.m. ET. TD Cowen 5th Annual Oncology Innovation Summit on Wedn...
Stella-Jones Announces First Quarter Results
Stella-Jones Announces First Quarter Results A strong start to the year following record financial performance in 2023 Sales of $775 million, up 9%, driven by organic sales growth in infrastructure product categoriesRecord first quarter EBITDA up 30% to $156 million, a margin of 20.1%Net income of $77 million or $1.36 per share, up 32% from Q1 2023 EPS MONTREAL, May 08, 2024 (GLOBE NEWSWIRE) -- Stella-Jones Inc. (TSX: SJ) (“Stella-Jones” or the “Company”) today announced financial results for its first quarter ended March 31, 2024. “I am pleased with our performance in the first quart...
Stella-Jones annonce ses résultats du premier trimestre
Stella-Jones annonce ses résultats du premier trimestre Un excellent début d'année après une performance financière record en 2023 Ventes de 775 millions $, en hausse de 9 %, portées par la croissance interne des catégories de produits d'infrastructures Hausse de 30 % du BAIIA qui atteint un niveau record au premier trimestre de 156 millions $, soit une marge de 20,1 % Résultat net de 77 millions $, soit 1,36 $ par action, en hausse de 32 % par rapport au RPA dégagé au T1-2023 MONTRÉAL, 08 mai 2024 (GLOBE NEWSWIRE) -- Stella-Jones Inc. (TSX: SJ) (« Stella-Jones » ou la « Sociét...
Akero Therapeutics to Present at the BofA Securities 2024 Health Care ...
Akero Therapeutics to Present at the BofA Securities 2024 Health Care Conference SOUTH SAN FRANCISCO, Calif., May 08, 2024 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, today announced that management will present at the BofA Securities 2024 Health Care Conference on Tuesday, May 14, 2024, at 5:00 p.m. P.T. in Las Vegas, NV. A live webcast of the Company presentation will be available through the investor relations section of the C...
Amicus Therapeutics to Present at the Bank of America 2024 Health Care...
Amicus Therapeutics to Present at the Bank of America 2024 Health Care Conference PRINCETON, N.J., May 08, 2024 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that management will participate in a fireside chat at the Bank of America 2024 Health Care Conference in Las Vegas, NV on Wednesday, May 15, 2024, at 1:40 p.m. P.T. A live audio webcast of the presentation can also be accessed via the investors section of the Amicus Therapeutics corporate website at . About Amicus Therapeutics Amicus Therapeutics (Nasdaq: FOLD) is a global, patient-dedicated biotechnology ...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.